Zhejiang Jiuzhou Pharmaceutical extends R&D project, boosts cash management

Huatai United Securities Co. issued a verification opinion on Zhejiang Jiuzhou Pharmaceutical's decision to extend the "Ruibo (Suzhou) Pharmaceutical Co. R&D Center Project" until December 31, 2026, from the original target of December 31, 2025. This extension, attributed to factors like engineering settlement progress, does not alter the project's scope, investment, or implementation body and is not expected to negatively impact the company’s normal operations. The project has utilized 23,118.49 thousand yuan of its 28,000.00 thousand yuan budget as of June 30, 2025, reaching an 82.57% investment progress.

Concurrently, Zhejiang Jiuzhou Pharmaceutical and its subsidiaries will utilize up to 1.00 bn yuan of idle raised funds and up to 1.20 bn yuan of idle自有 funds for cash management. These funds will be invested in highly secure, liquid products such as structured deposits and time deposits for a period not exceeding 12 months, aiming to enhance capital efficiency without affecting project implementation or core business. The company has engaged in similar cash management activities, with total actual investments reaching 91,500.00 thousand yuan and generating 670.15 thousand yuan in收益 from January to December 2024.

The board of directors approved these measures on December 9, 2025, emphasizing risk control and transparency. The related announcements underline the company’s strategy to optimize financial returns from idle capital while ensuring the continued progress of its investment projects.